|1.||Ruschitzka, Frank: 5 articles (08/2010 - 08/2002)|
|2.||Deja, Maria: 5 articles (08/2008 - 08/2002)|
|3.||Busch, Thilo: 5 articles (08/2008 - 08/2002)|
|4.||Kaisers, Udo: 5 articles (08/2008 - 08/2002)|
|5.||Boemke, Willehad: 5 articles (08/2008 - 08/2002)|
|6.||Petersen, Bodil: 5 articles (08/2008 - 08/2002)|
|7.||Bakris, George L: 3 articles (01/2011 - 10/2007)|
|8.||Linas, Stuart: 3 articles (11/2010 - 10/2007)|
|9.||Linseman, Jennifer V: 3 articles (11/2010 - 10/2007)|
|10.||Lüscher, Thomas F: 3 articles (08/2010 - 07/2004)|
|1.||Hypertension (High Blood Pressure)
08/01/2010 - "While results from early clinical studies suggested that darusentan might emerge as new treatment option in patients with resistant hypertension, results from recent studies suggests that darusentan appears unlikely to find its way in the armamentarium for treatment of resistant hypertension."
07/01/2008 - "Darusentan represents a novel treatment strategy for patients with resistant hypertension. "
07/01/2008 - "Studies evaluating the role of the ETS in CVD and the pharmacology, pharmacokinetics, safety, and efficacy of darusentan for the treatment of hypertension and CHF were included. "
01/01/2011 - "Studies with darusentan as an add-on therapy in patients with resistant hypertension found a significant BP-lowering effect of 17/10 mm Hg compared to placebo. "
11/01/2010 - "Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial."
08/01/2002 - "Treatment with darusentan over 21 days improved cGMP generation in patients with chronic heart failure."
07/24/2004 - "Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial."
01/01/2004 - "Consecutive patients with severe heart failure (New York Heart Association [NYHA] Grade III) were included in this neurohumoral sub-study of an international, multi-center, double-blind, placebo-controlled study of darusentan, and randomized to darusentan (n = 23) or placebo (n = 8). "
08/01/2002 - "Patients with chronic heart failure (n=142; mean age=57 years) received oral treatment with the ET(A) antagonist darusentan (either 30, 100, 300 mg/day or placebo) on top of standard therapy over a period of 21 days in a randomized, double-blind, placebo-controlled, multicentre study. "
01/01/2001 - "We evaluated the effects of chronic therapy with the selective ET(A)receptor antagonist LU 135252 (LU) on pulmonary vascular reactivity in congestive heart failure. "
07/01/2008 - "Additional studies in CHF are warranted to assess the safety and efficacy of darusentan, especially given its association with peripheral edema and decreased red blood cell count. "
01/01/2011 - "Darusentan, however, was associated with a high incidence of peripheral edema and fluid retention, a side effect that may reduce the safety profile of the drug and its tolerability. "
11/01/2010 - "The most frequent adverse event associated with darusentan was fluid retention/edema at 28% versus 12% in each of the other groups. "
07/01/2008 - "Darusentan is well tolerated, with only peripheral edema, headache, and nasal symptoms being reported more frequently than with placebo. "
10/01/2007 - "Darusentan was generally well tolerated; mild to moderate edema and headache were the most common adverse events. "
|4.||Acute Lung Injury
08/01/2008 - "We recently demonstrated that inhalation of the endothelin receptor A (ETA) antagonist LU 135252 improved arterial oxygenation and reduced pulmonary artery pressure in experimental acute lung injury (ALI). "
08/01/2002 - "To investigate the hypothesis that the inhaled ET(A) receptor antagonist LU-135252 acts as selective pulmonary vasodilator, we compared inhaled LU-135252 and inhaled nitric oxide (iNO) in an experimental model of acute lung injury (ALI), in a prospective, randomized, controlled animal study. "
11/01/2004 - "We studied the effects of the inhaled endothelin-A receptor antagonist LU-135252 at different doses on hemodynamics and gas exchange in an animal model of acute lung injury. "
11/01/2004 - "Inhalation of the endothelin-A receptor antagonist LU-135252 at various doses in experimental acute lung injury."
|1.||Endothelin A Receptor
|2.||Endothelin Receptors (Endothelin Receptor)
|5.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|6.||salicylhydroxamic acid (SHAM)
|7.||propionic acid (potassium propionate)
|1.||Surgical Instruments (Clip)